NVCT RSI Chart
Last 7 days
-3.7%
Last 30 days
-8.9%
Last 90 days
-18.1%
Trailing 12 Months
-63.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 810.0K | 0 | 0 | 0 |
2023 | 199.0K | 259.0K | 475.0K | 637.0K |
2022 | 40.3K | 76.5K | 112.8K | 149.0K |
2021 | 0 | 0 | 0 | 4.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 18, 2024 | bentsur ron | bought | 51,450 | 10.29 | 5,000 | chairman & ceo |
Jan 03, 2024 | poradosu enrique | acquired | - | - | 130,000 | chief science & business off |
Jan 03, 2024 | shemesh shay | acquired | - | - | 130,000 | chief dev. & ops. officer |
Oct 10, 2023 | bentsur ron | bought | 7,091 | 11.08 | 640 | chairman & ceo |
Oct 09, 2023 | bentsur ron | bought | 9,287 | 11.19 | 830 | chairman & ceo |
Oct 06, 2023 | bentsur ron | bought | 2,817 | 11.27 | 250 | chairman & ceo |
Oct 05, 2023 | bentsur ron | bought | 15,526 | 11.09 | 1,400 | chairman & ceo |
Oct 04, 2023 | bentsur ron | bought | 19,929 | 10.95 | 1,820 | chairman & ceo |
Aug 16, 2023 | bentsur ron | bought | 1,742 | 15.15 | 115 | chairman & ceo |
Aug 15, 2023 | bentsur ron | bought | 3,369 | 14.34 | 235 | chairman & ceo |
Which funds bought or sold NVCT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.97 | -4,083 | 6,125 | -% |
May 15, 2024 | DEUTSCHE BANK AG\ | new | - | 28,774 | 28,774 | -% |
May 15, 2024 | STATE STREET CORP | added | 9.38 | 74,461 | 1,060,910 | -% |
May 15, 2024 | MORGAN STANLEY | added | 79.76 | 146,657 | 337,767 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -49.7 | -31,637 | 30,955 | -% |
May 15, 2024 | BARCLAYS PLC | added | 0.38 | -2,000 | 84,000 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -33.41 | -3,681 | 6,978 | -% |
May 15, 2024 | MARSHALL WACE, LLP | added | 101 | 203,618 | 410,558 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 16.14 | 40,256 | 323,908 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -189,910 | - | -% |
Unveiling Nuvectis Pharma, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Nuvectis Pharma, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Nuvectis Pharma, Inc. News
Income Statement (Quarterly) | |||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -7.8% | 225,000 | 244,000 | 277,000 | 64,000 | 52,000 | 82,000 | 61,000 | 4,000 | 2,000 | - |
S&GA Expenses | -100.0% | - | 2,601,000 | 1,672,000 | 1,510,000 | 1,734,000 | 2,381,000 | 1,418,000 | 1,068,000 | 1,140,000 | 1,121,000 |
R&D Expenses | -37.6% | 2,660,000 | 4,265,000 | 4,486,000 | 4,262,000 | 2,367,000 | 4,397,000 | 4,520,000 | 2,505,000 | 1,805,000 | - |
Net Income | 37.0% | -4,171,000 | -6,622,000 | -5,881,000 | -5,708,000 | -4,049,000 | -6,696,000 | -5,877,000 | -3,569,000 | -2,943,000 | -2,261,000 |
Net Income Margin | 20.9% | -27.63 | -34.95 | -47.02 | -86.22 | -101 | -128 | -129 | -175 | -392 | -3,222 |
Free Cashflow | -13.2% | -4,358,000 | -3,850,000 | -3,244,000 | -4,083,000 | -4,777,000 | -3,516,000 | -4,424,000 | -2,543,000 | -3,076,000 | - |
Balance Sheet | |||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 2.8% | 20.00 | 19.00 | 22.00 | 25.00 | 16.00 | 20.00 | 25.00 | 14.00 | 18.00 | 7.00 |
Current Assets | 2.8% | 20.00 | 19.00 | 22.00 | 25.00 | 16.00 | 20.00 | 25.00 | 14.00 | 18.00 | 6.00 |
Cash Equivalents | 1.8% | 19.00 | 19.00 | 22.00 | 25.00 | 16.00 | 20.00 | 24.00 | 14.00 | 17.00 | 6.00 |
Liabilities | -18.5% | 6.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 4.00 | 3.00 | 3.00 | 2.00 |
Current Liabilities | -18.5% | 6.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 4.00 | 3.00 | 3.00 | 2.00 |
Shareholder's Equity | 14.9% | 14.00 | 12.00 | 17.00 | 20.00 | 12.00 | 14.00 | 20.00 | 12.00 | 15.00 | - |
Retained Earnings | -7.7% | -58.40 | -54.20 | -47.60 | -41.74 | -36.03 | -31.98 | -25.29 | -19.40 | -15.80 | -12.90 |
Additional Paid-In Capital | 9.0% | 72.00 | 66.00 | 64.00 | 62.00 | 48.00 | 46.00 | 46.00 | 31.00 | 30.00 | 2.00 |
Shares Outstanding | 5.4% | 18.00 | 17.00 | 17.00 | 17.00 | 15.00 | 15.00 | 14.00 | 13.00 | 9.00 | 5.00 |
Float | -100.0% | - | 60.00 | - | - | - | 64.00 | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 |
Cashflow From Operations | -13.2% | -4,358 | -3,850 | -3,244 | -4,083 | -4,777 | -3,516 | -4,424 | -2,543 | -3,076 | - | - | - |
Share Based Compensation | 6.2% | 1,296 | 1,220 | 1,133 | 950 | 1,402 | 482 | 559 | 510 | 156 | - | - | - |
Cashflow From Investing | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | 412.1% | 4,696 | 917 | 703 | 13,215 | 252 | -131 | 14,492 | -578 | 14,027 | - | - | - |
CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
OPERATING EXPENSES | ||
Research and development | $ 2,660 | $ 2,367 |
General and administrative | 1,736 | 1,734 |
OPERATING LOSS | (4,396) | (4,101) |
Finance income | 225 | 52 |
NET LOSS | (4,171) | (4,049) |
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | $ (4,171) | $ (4,049) |
BASIC NET LOSS PER COMMON SHARES OUTSTANDING, see Note 6 | $ (0.25) | $ (0.27) |
DILUTED NET LOSS PER COMMON SHARES OUTSTANDING, see Note 6 | $ (0.25) | $ (0.27) |
Basic weighted average number of common shares outstanding | 16,559,335 | 14,724,249 |
Diluted weighted average number of common shares outstanding | 16,559,335 | 14,724,249 |
CONDENSED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 | ||
---|---|---|---|---|
CURRENT ASSETS | ||||
Cash and cash equivalents | $ 19,464 | $ 19,126 | ||
Other current assets | 250 | 59 | ||
TOTAL CURRENT ASSETS | 19,714 | 19,185 | ||
TOTAL ASSETS | 19,714 | 19,185 | ||
CURRENT LIABILITIES | ||||
Accounts payables | 1,759 | 2,771 | ||
Accrued liabilities | 486 | 415 | ||
Employee compensation and benefits | 3,447 | 3,798 | ||
TOTAL CURRENT LIABILITIES | 5,692 | 6,984 | ||
TOTAL LIABILITIES | 5,692 | 6,984 | ||
COMMITMENTS AND CONTINGENCIES, see Note 3 | ||||
SHAREHOLDERS' EQUITY see Note 4 | ||||
Common Shares, $0.00001 par value - 60,000,000 shares authorized as of March 31, 2024, and December 31, 2023, respectively, 18,356,060, and 17,418,886 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | [1] | |||
Additional paid in capital | 72,438 | 66,446 | ||
Accumulated deficit | (58,416) | (54,245) | ||
TOTAL SHAREHOLDERS' EQUITY | 14,022 | 12,201 | ||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ 19,714 | $ 19,185 | ||
|